AIM ImmunoTech to Join Virtual Investor Pitch Conference

OCALA, Fla., June 10, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) has revealed that its Chief Executive Officer, Thomas K. Equels, MS JD, will be involved in the Virtual Investor Pitch Conference scheduled for Monday, June 17, 2024, at 1:00 PM ET. The event will feature Mr. Equels delivering a concise "elevator pitch" and highlighting the company's forthcoming milestones.

During the conference, investors and interested parties will have the chance to engage directly by submitting live questions. The participating companies will endeavor to address as many inquiries as time permits.

The presentation will be broadcast live via a video webcast, which can be accessed on the Events page of AIM ImmunoTech's website (aimimmuno.com). For those unable to attend the live session, a webcast replay will be available two hours after the initial presentation and will remain accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a company specializing in immunopharmaceuticals, concentrating on the research and development of treatments for various cancers, immune disorders, and viral diseases, including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a pioneering investigational drug. Ampligen® is a double-stranded RNA and a highly selective Toll-Like Receptor 3 (TLR3) agonist immuno-modulator. It exhibits broad-spectrum activity and is currently undergoing clinical trials for multiple significant cancers, viral diseases, and immune system disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!